Trial Profile
A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to TNF-alpha Antagonist Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Genmab; GlaxoSmithKline; GSK
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain (End Date: 15 Jul 2013), according to European Clinical Trials Database record.
- 25 Jul 2019 This trial has been completed in United Kingdom according to European Clinical Trials Database record.